US coverage of LVADs (left ventricular assist devices) as destination therapy delayed
This article was originally published in Clinica
The sheer complexity of drafting a coverage decision is reportedly what is holding up Medicare's announcement on whether it intends to cover left ventricular assist devices (LVADs) as destination therapy for beneficiaries with failing hearts who do not qualify for a heart transplant.
You may also be interested in...
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.